These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19264792)

  • 1. Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy.
    Rehm S; Campion M; Katz DE; Russo R; Boucher HW
    J Antimicrob Chemother; 2009 May; 63(5):1034-42. PubMed ID: 19264792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.
    Rehm SJ; Boucher H; Levine D; Campion M; Eisenstein BI; Vigliani GA; Corey GR; Abrutyn E
    J Antimicrob Chemother; 2008 Dec; 62(6):1413-21. PubMed ID: 18782781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
    Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
    N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis.
    Kanafani ZA; Kourany WM; Fowler VG; Levine DP; Vigliani GA; Campion M; Katz DE; Corey GR; Boucher HW
    Eur J Clin Microbiol Infect Dis; 2009 Dec; 28(12):1477-82. PubMed ID: 19730900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
    Cosgrove SE; Vigliani GA; Fowler VG; Abrutyn E; Corey GR; Levine DP; Rupp ME; Chambers HF; Karchmer AW; Boucher HW
    Clin Infect Dis; 2009 Mar; 48(6):713-21. PubMed ID: 19207079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia.
    Lalani T; Boucher HW; Cosgrove SE; Fowler VG; Kanafani ZA; Vigliani GA; Campion M; Abrutyn E; Levine DP; Price CS; Rehm SJ; Corey GR; Karchmer AW;
    J Antimicrob Chemother; 2008 Jan; 61(1):177-82. PubMed ID: 17999973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infections.
    Jobson S; Moise PA; Eskandarian R
    Clin Ther; 2011 Oct; 33(10):1391-9. PubMed ID: 22015328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis.
    Bhavnani SM; Prakhya A; Hammel JP; Ambrose PG
    Clin Infect Dis; 2009 Sep; 49(5):691-8. PubMed ID: 19635023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin.
    Browne C; Muszbek N; Chapman R; Marsh K; Gould IM; Seaton RA; Allen M
    Int J Antimicrob Agents; 2016 May; 47(5):357-61. PubMed ID: 27061774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia.
    Arrieta AC; Bradley JS; Popejoy MW; Bensaci M; Grandhi A; Bokesch P; Glasser C; Du L; Patino H; Kartsonis NA
    Pediatr Infect Dis J; 2018 Sep; 37(9):893-900. PubMed ID: 29406465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftobiprole versus daptomycin in
    Hamed K; Engelhardt M; Jones ME; Saulay M; Holland TL; Seifert H; Fowler VG
    Future Microbiol; 2020 Jan; 15(1):35-48. PubMed ID: 31918579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
    Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
    Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes of Daptomycin Versus Anti-Staphylococcal Beta-Lactams in Definitive Treatment of Methicillin-susceptible Staphylococcus aureus Bloodstream Infections.
    Agnello S; Wardlow LC; Reed E; Smith JM; Coe K; Day SR
    Int J Antimicrob Agents; 2021 Aug; 58(2):106363. PubMed ID: 34033912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
    Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS;
    JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial.
    Cheng MP; Lawandi A; Butler-Laporte G; Paquette K; Lee TC
    Trials; 2018 May; 19(1):297. PubMed ID: 29843781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.
    Moise PA; Amodio-Groton M; Rashid M; Lamp KC; Hoffman-Roberts HL; Sakoulas G; Yoon MJ; Schweitzer S; Rastogi A
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1192-200. PubMed ID: 23254428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study.
    Kalimuddin S; Chan YFZ; Phillips R; Ong SP; Archuleta S; Lye DC; Tan TT; Low JGH
    Trials; 2018 Jun; 19(1):305. PubMed ID: 29859132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.
    Hair PI; Keam SJ
    Drugs; 2007; 67(10):1483-512. PubMed ID: 17600394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.
    Bhavnani SM; Ambrose PG; Hammel JP; Rubino CM; Drusano GL
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1600-7. PubMed ID: 26711755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.